Gaudium IVF and Women Health Limited GAUDIUMIVF NSEPHARMA
Company Overview
Gaudium IVF and Women Health Limited provides in vitro fertilization (IVF) treatment in India. The company offers fertility and reproductive health services, including intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and ovulation induction; polycystic ovarian syndrome (PCOS)/ polycystic ovarian disease (PCOD); endometriosis treatment; ovulation induction; and laser assisted embryo implantation services. It also provides male infertility treatment services; egg freezing; embryo freezing; frozen embryo transfer; gynae consultation; laparoscopy for infertility; diagnostic services; and support and counselling services. In addition, the company operates hospital, in-house pharmacy; and 7 hubs (IVF centers) and 28 spokes. The company was founded in 2009 and is based in headquartered in New Delhi, India.
Why Investors Should Care
Generates a return on equity of 16.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 23.1%.
Net profit has compounded at 21.9% per year over the last five years.
Revenue has grown at a 33.1% CAGR over the past five years.
Trades at a P/E of 35.5, below the sector median of 40.0.
Maintains a net profit margin of 21.9%.
Recent Developments
- Mar 2026 Revenue of ₹104.36 Cr (+47.6% YoY); net profit ₹24.49 Cr.
- Trailing 12 Months Year-on-year growth — revenue +9.1%, earnings -50.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 33.1%, profit CAGR 21.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 33.12% |
| 1 Year: | 9.10% |
Compounded Profit Growth
| 5 Years: | 21.88% |
| 1 Year: | -50.00% |
Stock Price Performance
| 1 Year: | +40.49% |
| 6 Months: | +53.23% |
| 3 Months: | +8.80% |
| 1 Month: | -13.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)37.10 · Neutral
P/E of 35.46 is below the sector median of 40.02 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 23.1%.
- Excellent profit margin of 21.9%.
- Compounding revenue at 33.1% over 5 years.
- Profit CAGR of 21.9% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 28.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GAUDIUMIVF Gaudium IVF and Women Health Limited NSEPHARMA | 112.76 | 35.46 | ₹820.74 Cr | 0.00% | 23.09% | 16.08% | 33.12% | 21.88% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,895.00 | 37.64 | ₹4.55 L Cr | 0.85% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,315.00 | 84.60 | ₹2.47 L Cr | 0.31% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,914.00 | 78.62 | ₹1.87 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.23% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 688.00 | 237.24 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,156.90 | 23.10 | ₹1.16 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 33.25 | ₹1.12 L Cr | 0.94% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 90.86 | ₹99,417.45 Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 14.42 Cr | 26.92 Cr | 24.51 Cr | 30.35 Cr |
| Cost of Revenue | 5.00 Cr | 14.19 Cr | 15.11 Cr | 12.55 Cr |
| Gross Profit | 9.42 Cr | 12.74 Cr | 9.39 Cr | 17.80 Cr |
| Operating Expenses | 4.34 Cr | 4.38 Cr | 3.34 Cr | 6.26 Cr |
| Operating Income | 5.08 Cr | 8.36 Cr | 6.06 Cr | 11.54 Cr |
| EBITDA | 5.66 Cr | 8.96 Cr | 6.65 Cr | 12.35 Cr |
| Interest Expense | 38.99 L | 43.44 L | 1.20 Cr | 1.29 Cr |
| Pretax Income | 4.69 Cr | 8.16 Cr | 4.96 Cr | 10.42 Cr |
| Tax Provision | 1.30 Cr | 1.70 Cr | 1.33 Cr | 2.06 Cr |
| Net Income | 3.40 Cr | 6.46 Cr | 3.63 Cr | 8.36 Cr |
| Diluted EPS | 0.43 | 0.81 | 0.50 | 1.34 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 44.24 Cr | 47.89 Cr | 70.72 Cr | 104.36 Cr |
| Cost of Revenue | - | 14.12 Cr | 15.89 Cr | 27.79 Cr | 50.04 Cr |
| Gross Profit | - | 30.12 Cr | 32.00 Cr | 42.93 Cr | 54.32 Cr |
| Operating Expenses | - | 11.34 Cr | 14.41 Cr | 16.35 Cr | 19.16 Cr |
| Operating Income | - | 18.78 Cr | 17.59 Cr | 26.58 Cr | 35.16 Cr |
| EBITDA | - | 20.09 Cr | 19.54 Cr | 28.87 Cr | 38.24 Cr |
| Interest Expense | - | 34.24 L | 74.75 L | 1.39 Cr | 3.49 Cr |
| Pretax Income | - | 18.31 Cr | 16.63 Cr | 25.43 Cr | 32.20 Cr |
| Tax Provision | - | 4.79 Cr | 6.31 Cr | 6.25 Cr | 7.71 Cr |
| Net Income | - | 13.53 Cr | 10.32 Cr | 19.18 Cr | 24.49 Cr |
| Diluted EPS | 1.11 | 1.86 | 1.42 | 2.40 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 36.63 Cr | 51.01 Cr | 88.51 Cr | 193.10 Cr |
| Current Assets | - | 18.39 Cr | 29.52 Cr | 53.81 Cr | 73.30 Cr |
| Cash & Equivalents | - | 15.06 Cr | 11.86 Cr | 7.21 Cr | 8.79 Cr |
| Inventory | - | 1.50 Cr | 2.10 Cr | 7.23 Cr | 3.54 Cr |
| Receivables | - | 90.84 L | 13.59 Cr | 32.87 Cr | 53.38 Cr |
| Total Liabilities | - | 13.90 Cr | 24.02 Cr | 42.22 Cr | 40.80 Cr |
| Current Liabilities | - | 9.60 Cr | 19.69 Cr | 38.01 Cr | 38.53 Cr |
| Long Term Debt | - | 2.11 Cr | 1.93 Cr | 1.73 Cr | 0 |
| Total Debt | - | 11.55 Cr | 17.40 Cr | 20.61 Cr | 24.57 Cr |
| Total Equity | - | 22.73 Cr | 26.99 Cr | 46.30 Cr | 152.30 Cr |
| Shares Outstanding | - | 7.28 Cr | 7.28 Cr | 7.28 Cr | 7.28 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 23.85 Cr | 3.44 Cr | 8.72 Cr | 7.25 Cr |
| Investing Cash Flow | - | -15.63 Cr | -5.40 Cr | -15.17 Cr | -87.65 Cr |
| Financing Cash Flow | - | 5.25 Cr | -1.24 Cr | 1.82 Cr | 81.98 Cr |
| Capital Expenditure | - | -15.26 Cr | -2.79 Cr | -8.88 Cr | -6.72 Cr |
| Free Cash Flow | - | 8.60 Cr | 65.40 L | -16.08 L | 52.81 L |
| Net Change in Cash | - | 13.48 Cr | -3.20 Cr | -4.64 Cr | 1.57 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 68.1% | 66.8% | 60.7% | 52.1% |
| Operating Margin % | - | 42.4% | 36.7% | 37.6% | 33.7% |
| Net Margin % | - | 30.6% | 21.5% | 27.1% | 23.5% |
| ROE % | - | 59.5% | 38.2% | 41.4% | 16.1% |
| ROCE % | - | 69.5% | 56.2% | 52.6% | 22.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GAUDIUMIVF
Gaudium IVF and Women Health's (NSE:GAUDIUMIVF) Profits May Not Reveal Underlying Issues - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPcWhGTVpKZ3Z3aEdGV1N0SmxtcFM0Z3p4VWNMZmRXdUFZYmNXdDJoR0F3NXZKTjNLZFc0QkhiM2ZEVC1XMVJQT2V6bWxrZnZOUzM0bFhaY3dFODNfd0djV3JNOVNNMEo4azBXa2xoVG92QXdmSDd1VTJmXzJlSXA4RkpsWFF5RjlRS0ZUVW…
GAUDIUM IVF N WOMEN H L Share Price - Live NSE: GAUDIUMIVF Stock Price & Chart - upstox.com
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE9ZdnFmeFRUWFRpNkNWdWk5Q0NjcTg4WGFfX2tBU3dsQWJOdlVzbXg0M0tManZYYlpHQWI3OHc5UEFxcVhVTVlkSzctLWl0VE9qcUtQaVVRSjVHNjZ0NzdyWE54V2xTQXlWNUxwYTJHRQ?oc=5" target="_blank">GAUDIUM IVF N WOM…
Price to book forward of Gaudium IVF & Women Health Ltd. – NSE:GAUDIUMIVF - TradingView
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOWE1jX0dnYnBDN21CelgxQTV5MHd4WGtZdE9GOGlta0thNV9lNGJjZEFBOXZiZzZGcmE4Z2phV3hvS2d0eFltZk43VzF5eEFHVTdvX3RlZ3RFc2cydmk5WW9yMVZOd0wtUnA3UHRjVHBPaEdFM3hlVUFiOUd4c3JfOTVnNktma3RjU2dJa2…
Gaudium IVF Slips 2% as Resistance Caps Gains; Support Levels in Focus - Earnings Sentiment - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOQ0ZTYTVCZGk5VkxFRndxQXlobk5yUE1ycHQ3TkpHaW83Zks5ZWdFU3d0bFVxLUJiSHZBQUxvNGl0WjBVbzg2dVlFbGxWMDV0bUhlUzBNSkltWVpzVDcxaU03YUt3RFpjOGNhRk1VbXZWR0hNVEVycWpPOG5xQU5Sb2ZEeTNlbzJFZG9MZU…
Price Band Hitters | July 20, 2026 - HDFC Sky
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE1pUVFjaGVyLWtMTXFZdjJPQ3lJQVJWdWNuazgwM3RVR29NQ2owWmpYZFc5amNweU16WWI1TmtSWVliamF0U21EeUYyemxoVWpac0J4RzAxTUtERWRvS1h2RmpCYTNKX09mZXJacU85dw?oc=5" target="_blank">Price Band Hitter…
Gaudium IVF and Women Health Ltd Share Price Today – Live NSE/BSE - INDmoney
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxNNXFRWk5hSXZlLXYtbVpMRTdpWWN5RE9mcnNsTFFOZnZTLVNXMTlnb19YZWhRZDhfemh6c0swRVA4SkN6UWZCQkkzTW5TTWQ1YU9aTS1mQlZ4MjVpS0I5OXlRTmhoNV9sajZEcGJ6b1AwTGE3ZHBncjhsVmh0RnNYSjB3?oc=5" target=…
GAUDIUMIVF — Frequently Asked Questions
What is the current share price of Gaudium IVF and Women Health Limited (GAUDIUMIVF)?
As of 2026-09-20 09:43 IST, Gaudium IVF and Women Health Limited (GAUDIUMIVF) trades at ₹112.76 on NSE. Its 52-week range is ₹70.67 to ₹158.16.
What is the market capitalisation of GAUDIUMIVF?
Gaudium IVF and Women Health Limited (GAUDIUMIVF) has a market capitalisation of ₹820.74 Cr on NSE.
What is the P/E ratio of GAUDIUMIVF?
GAUDIUMIVF trades at a trailing price-to-earnings (P/E) ratio of 35.46. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 4.77.
What is the return on equity (ROE) of GAUDIUMIVF?
GAUDIUMIVF has a return on equity (ROE) of 16.08%. Its return on capital employed (ROCE) is 23.09%.
Is GAUDIUMIVF a good stock to buy?
This page provides a data-driven analysis of Gaudium IVF and Women Health Limited (GAUDIUMIVF), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.